Integra LifeSciences executives will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Quiver AI Summary
Integra LifeSciences Holdings Corporation announced that CEO Mojdeh Poul and CFO Lea Knight will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. A live webcast of the presentation will be available on the company's investor relations website. Integra LifeSciences is focused on restoring patients' lives through innovative treatment pathways and has a comprehensive portfolio of high-quality medical technologies in surgical, neurologic, and regenerative care. For more information, interested parties can visit their website or contact their investor relations and media representatives.
Potential Positives
- Integra LifeSciences Holdings Corporation's participation in the prestigious 44th Annual J.P. Morgan Healthcare Conference highlights the company's prominence and credibility in the medical technology sector.
- The presentation by the CEO and CFO suggests a proactive approach to engaging with investors and stakeholders, which may enhance investor confidence.
- The availability of a live webcast allows for greater accessibility to a wider audience, potentially increasing interest in the company's initiatives and products.
Potential Negatives
- None
FAQ
When is Integra LifeSciences presenting at the J.P. Morgan Healthcare Conference?
Integra LifeSciences will present on January 14, 2026, at 2:15 p.m. ET.
Who are the presenters for Integra LifeSciences at the conference?
The presenters are Mojdeh Poul, CEO, and Lea Knight, CFO.
How can I watch the Integra LifeSciences presentation?
A live webcast will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.
What is the purpose of Integra LifeSciences?
Integra LifeSciences is dedicated to restoring patients' lives by innovating treatment pathways and improving patient outcomes.
Where can I find more information about Integra LifeSciences?
For the latest news and information, visit Integra LifeSciences' website at www.integralife.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IART Insider Trading Activity
$IART insiders have traded $IART stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IART stock by insiders over the last 6 months:
- JEFFREY A GRAVES purchased 9,000 shares for an estimated $102,150
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IART Revenue
$IART had revenues of $402.1M in Q3 2025. This is an increase of 5.57% from the same period in the prior year.
You can track IART financials on Quiver Quantitative's IART stock page.
$IART Hedge Fund Activity
We have seen 97 institutional investors add shares of $IART stock to their portfolio, and 109 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KENT LAKE PR LLC added 752,086 shares (+inf%) to their portfolio in Q3 2025, for an estimated $10,777,392
- ASSENAGON ASSET MANAGEMENT S.A. removed 739,827 shares (-62.0%) from their portfolio in Q3 2025, for an estimated $10,601,720
- NEUBERGER BERMAN GROUP LLC added 676,618 shares (+78.8%) to their portfolio in Q3 2025, for an estimated $9,695,935
- MILLENNIUM MANAGEMENT LLC removed 611,848 shares (-73.1%) from their portfolio in Q3 2025, for an estimated $8,767,781
- J. GOLDMAN & CO LP added 598,498 shares (+169.9%) to their portfolio in Q3 2025, for an estimated $8,576,476
- RUBRIC CAPITAL MANAGEMENT LP added 300,000 shares (+4.1%) to their portfolio in Q3 2025, for an estimated $4,299,000
- JANE STREET GROUP, LLC removed 298,275 shares (-93.8%) from their portfolio in Q3 2025, for an estimated $4,274,280
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IART Analyst Ratings
Wall Street analysts have issued reports on $IART in the last several months. We have seen 0 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Sell" rating on 10/31/2025
- JP Morgan issued a "Underweight" rating on 10/31/2025
To track analyst ratings and price targets for $IART, check out Quiver Quantitative's $IART forecast page.
$IART Price Targets
Multiple analysts have issued price targets for $IART recently. We have seen 4 analysts offer price targets for $IART in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Ravi Misra from Truist Securities set a target price of $13.0 on 11/03/2025
- Joanne Wuensch from Citigroup set a target price of $11.0 on 10/31/2025
- Robbie Marcus from JP Morgan set a target price of $13.0 on 10/31/2025
Full Release
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m ET or 11:15 a.m PT
A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS .
About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit
www.integralife.com
.
Investor Relations:
Chris Ward
(609) 772-7736
[email protected]
Media Contact:
Laurene Isip
(609) 208-8121
[email protected]
Integra LifeSciences Holdings Corporation
